Multiple dose design Sample size [Power / Sample Size]

posted by Researcher101 – Egypt, 2020-10-14 15:37 (846 d 00:23 ago) – Posting: # 22000
Views: 1,554

(edited by on 2020-10-19 10:41)

Also if Cmax ss within variability is around 20 % and Cmin ss within variability is around 41 % on which one should I depend


Dears, I am asking about the factor we determine the sample size in multiple dose studies? Should I estimate sample size based on intra subject variability of Cmin or Cmax or C tau?

Can I pool the CVs to estimate sample size?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]

Edit: Post merged with a new (deleted) post of 2020-10-19. Relax; see also this post #9[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
16 visitors (0 registered, 16 guests [including 7 identified bots]).
Forum time: 15:01 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5